
MyD88 Fusion Protein with Antigen Specific T Cell Therapy for Enhanced Response in Solid TumorsAward last edited on: 4/7/2021
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$397,422Award Phase
1Solicitation Topic Code
395Principal Investigator
Samantha DunmireCompany Information
Phase I
Contract Number: 1R43CA254794-01Start Date: 9/8/2020 Completed: 8/31/2021
Phase I year
2020Phase I Amount
$397,422Public Health Relevance Statement:
Project Narrative T cells expressing mesothelin reactive T cell receptors (TCRs) can recognize and kill pancreatic cancer cells in vitro, but suppression within the tumor microenvironment and poor persistence limit in vivo efficacy. This proposal seeks to develop a T cell therapy based on co-expression of mesothelin specific TCRs with the co-stimulatory CD8?:MyD88 fusion protein, which has been shown to substantially increase T cell function, persistence, and tumor clearance in vivo in mice. Given treatment options are limited for pancreatic cancer patients and prognosis remains poor, this technology represents a novel method for enhancing T cell therapies and may significantly increase the survival of patients with pancreatic cancer.
Project Terms:
advanced pancreatic cancer; Affect; Affinity; Animal Model; Antigen Receptors; antigen-specific T cells; Antigens; Antitumor Response; Autologous; base; Biotechnology; Cancer Prognosis; cancer therapy; CD4 Positive T Lymphocytes; CD8 receptor; CD8-Positive T-Lymphocytes; CD8B1 gene; cell killing; Cell Line; Cell model; Cell physiology; Cell Therapy; Cells; chimeric antigen receptor; Chimeric Proteins; Clinical Trials; clinically relevant; cytokine; cytotoxic; Cytotoxic T-Lymphocytes; cytotoxicity; Data; density; design; effective therapy; efficacy testing; engineered T cells; Enhancers; exhaustion; Exhibits; experience; Future; Gene Transfer; Genetic Engineering; HLA-A2 Antigen; Human; Human Resources; Immune; Immune signaling; Immunosuppression; Immunotherapeutic agent; Immunotherapy; Impairment; improved; In Vitro; in vitro activity; in vivo; Inflammatory; innovation; Longevity; Malignant neoplasm of pancreas; Membrane; Memory; mesothelin; Methods; mouse model; Mus; neoplastic cell; novel; outcome forecast; overexpression; pancreatic cancer cells; pancreatic cancer model; pancreatic cancer patients; Pancreatic Ductal Adenocarcinoma; pancreatic neoplasm; Pathway interactions; patient subsets; Patient-Focused Outcomes; Peptides; peripheral tolerance; Phase; Phenotype; Physiologic pulse; pre-clinical; prevent; Production; Property; protein aminoacid sequence; Protein Engineering; Publishing; receptor; response; Safety; Signal Transduction; Solid Neoplasm; Specificity; Stains; stem; Study models; success; Surface; Survival Rate; T cell therapy; T Chain; T-Cell Proliferation; T-Cell Receptor; T-Lymphocyte; technological innovation; Technology; Technology Transfer; Testing; Therapeutic; Toxic effect; Transgenic Mice; Transgenic Organisms; tumor; Tumor Burden; tumor microenvironment; tumor-immune system interactions; Validation; Variant; vector; virtual; Work; Xenograft procedure
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00